Stock CLGN COLLPLANT BIOTECHNOLOGIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

CollPlant Biotechnologies Ltd.

Equities

CLGN

IL0004960188

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
5.4 USD +2.66% Intraday chart for CollPlant Biotechnologies Ltd. +4.62% -15.49%
Apr. 04 CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 02 CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $43,000 MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
CollPlant Biotechnologies Issued US Patent for Photocurable Dermal Filler MT
Wall Street Set to Open Slightly Higher; Weekly Jobless Claims Fall to Near Historic Lows MT
Top Premarket Decliners MT
Earnings Flash (CLGN) COLLPLANT Reports Q2 Revenue $10.2M MT
Earnings Flash (CLGN) COLLPLANT Posts Q2 EPS $0.52 MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CollPlant to Receive $10 Million Milestone Payment From AbbVie Under Dermal Filler Product Deal; Shares Rise MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Stratasys, CollPlant Biotechnologies to Bio-Fabricate Human Tissues, Organs MT
Stratasys Ltd. and Collplant Biotechnologies Ltd. to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs CI
HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating MT
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives CI
Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $109,000 MT
Earnings Flash (CLGN) COLLPLANT Posts Q3 Loss $-0.34 MT
CollPlant, Tel Aviv University, Sheba Medical Center to Co-Develop Tissue Model for Drug Discovery to Treat Ulcerative Colitis MT
Collplant Enters into A License and Research Agreement to Co-Develop A “Gut-On-A-Chip” Tissue Model for Drug Discovery and High Throughput Screening of Drugs CI
CollPlant Biotechnologies Ltd., Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis CI
Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90 CI

Chart CollPlant Biotechnologies Ltd.

Chart CollPlant Biotechnologies Ltd.
More charts

Company Profile

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Sector
Biotechnology & Medical Research
Calendar
2024-05-22 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CollPlant Biotechnologies Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.4 USD
Average target price
11 USD
Spread / Average Target
+103.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

1st Jan change Capi.
COLLPLANT BIOTECHNOLOGIES LTD. Stock CollPlant Biotechnologies Ltd.
-15.49% 61.84M
MIMEDX GROUP, INC. Stock MiMedx Group, Inc.
-25.77% 961M
NIBEC CO., LTD. Stock NIBEC Co., Ltd.
-19.12% 131M
KIM FOREST ENTERPRISE CO., LTD. Stock Kim Forest Enterprise Co., Ltd.
+10.84% 63.05M
NOVACYT Stock Novacyt
+13.60% 61.14M
BONUS BIOGROUP LTD. Stock Bonus BioGroup Ltd.
-1.20% 50.36M
Bio Medical Devices
  1. Stock Market
  2. Equities
  3. CLGN Stock
  4. News CollPlant Biotechnologies Ltd.
  5. Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $140,000